Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection—a randomized controlled study
- 494 Downloads
Endoscopic submucosal dissection (ESD) is useful for treating gastric tumors. Several trials have shown the efficacy of 4 or 8 weeks of proton pump inhibitor (PPI) administration for post-ESD ulcers. However, if the size of the post-ESD ulcer is larger than predicted, PPI administration alone might not be sufficient for the ulcer to heal within 4 weeks. We examined the efficacy of a combination therapy of PPI and rebamipide, a mucosal-protective antiulcer drug, on the acceleration of post-ESD ulcer healing.
Patients were randomly assigned to either the PPI and rebamipide therapy or the PPI alone. Sixty-two consecutive patients with gastric tumors gave informed consent for enrolling in the study. In all cases, the estimated size of the post-ESD ulcer was larger than 20 mm. Oral administration of the drug was started on the 2nd day post-ESD and continued to the 28th day.
All patients received the assigned pharmaceuticals and adhered well to the treatment regimen for 28 days. The endpoint ulcers reached S1 (scar stage) in 11/31 (36%) patients in the PPI-only group and in 21/31 (68%) in the combination group (P = 0.010).
The combination of PPI plus rebamipide was more effective than the PPI alone for treating ulcers larger than 20 mm within 4 weeks after ESD.
KeywordsEndoscopic mucosal resection (EMR) Endoscopic submucosal dissection (ESD) Histamine H2 receptor antagonist (H2RA) Proton pump inhibitor (PPI) Rebamipide Gastric tumor Gastric cancer Ulcer healing
Conflict of interest statement
- 5.Uedo N, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007;102:1610–6.CrossRefPubMedGoogle Scholar
- 9.Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobactor pylori in Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42:690–3.CrossRefPubMedGoogle Scholar
- 12.Du T, Li Z, Zhan X, Chen J, Gao J, Gong Y, et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China—STARS study. Dig Dis Sci. 2008;53:2886–95.CrossRefPubMedGoogle Scholar
- 17.Sakita T, Fukutomi H. Endoscopic diagnosis. In: Yoshitoshi Y, editor. Ulcer of the stomach and duodenum (in Japanese). Tokyo: Nankodo; 1971. p. 198–208.Google Scholar
- 22.Yamaguchi Y, Katsumi N, Tauchi M, Toki K, Nakamura K, Aoki Y, et al. A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. Aliment Pharmacol Ther. 2005;21:111–5.CrossRefPubMedGoogle Scholar